MedTrace Logo

Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Receiving Weekly Docetaxel

NCT00215748 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2007-11-16

No results posted yet for this study

Summary

This study is to explore the feasibility of an alternative dose of dexamethasone pre-medication in older breast and lung cancer patients who are receiving weekly docetaxel chemotherapy.

Conditions

Interventions

DRUG

Dexamethasone

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Geriatric Oncology Consortium

    lead OTHER

Principal Investigators

  • William Ershler, MD · Geriatric Oncology Consortium

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Completion
2007-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00215748 on ClinicalTrials.gov